Drug Combination Details
| General Information of the Combination (ID: C20416) | |||||
|---|---|---|---|---|---|
| Name | Daidzein NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCH89 | CVCL_S823 | Glioblastoma | Homo sapiens | ||
| LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | |||
| Experimental
Result(s) |
Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. Neurosci Lett. 2009 May 1;454(3):223-8. | |||
